BioSpace News Archive

Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 17 abstracts from its industry-leading cell therapy portfolio and growing blood cancer pipeline at the upcoming 2023 European Hematology Association (EHA).

Royal Philips announced FDA clearance allowing the activation of SedLine® Brain Function Monitoring, Regional Oximetry, and CO2 measurements in Philips Patient Monitors – IntelliVue MX750 and MX850.

Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, will be highlighting new studies and the recent expansion of its Precise™ Oncology Solutions portfolio at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting from June 2-6, 2023.

Pasithea Therapeutics Corp. announced that pre-clinical results for its lead drug candidate, PAS-004, have been accepted for a poster presentation at the 2023 Neurofibromatosis Conference taking place June 24-27, 2023, in Scottsdale, Arizona.

Daré Bioscience, Inc., a leader in women’s health innovation, announced that Sabrina Martucci Johnson, the company’s President and CEO, will participate in two conferences during the week of June 5th:

Aerami Therapeutics announced new additions to its management team as the company prepares for the imminent initiation of the planned “uniPHied” Phase 2 trial of AER-901, in pulmonary hypertension associated with interstitial lung disease and pulmonary arterial hypertension.

Catalyst Pharmaceuticals, Inc. reported positive momentum for the second quarter of 2023 and reaffirmed its full-year 2023 total revenue guidance of between $375 million and $385 million, representing a 75% to 80% increase in total revenues compared to 2022.

Exact Sciences Corp. announced that the company has been certified as a 2023 Great Place To Work® for the fifth consecutive year.

BIORCHESTRA today announced that Dr. Branden Ryu, Founder, Chairman, and Chief Executive Officer, has accepted an invitation to present the company’s discovery program, brain-specific gene targeted siRNA-BTRiN and non human primate (NHP) study outcomes from its lead program – BMD-001 – at the 2023 Biotechnology Innovation Organization International Convention.

INOVIO today announced that it has made an equity grant to a newly hired employee under its 2022 Inducement Plan.